Clinical Trials
15 trialsNCT07605962 2026-05-26
Phase 1/2 Study of UI-102 in Selected Advanced Cancers
United Immunity, co., Ltd.
Phase 1/2 Not yet recruiting
NCT06656390 2026-05-22
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), and Antitumor Activity of ALK201 in Participants With Advanced Solid Tumors
Shanghai Allink Biotherapeutics Co., Ltd.
Phase 1/2 Recruiting
NCT03459222 2026-04-06
An Investigational Study of Immunotherapy Combinations in Participants With Solid Cancers That Are Advanced or Have Spread
Bristol-Myers Squibb
Phase 1/2 Completed
NCT03994601 2026-01-20
An Investigational Immunotherapy Study of BMS-986288 Alone and in Combination With Nivolumab in Advanced Solid Cancers
Bristol-Myers Squibb
Phase 1/2 Completed
NCT04495296 2025-12-19
A Trial to Evaluate Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of TST001 in Advanced or Metastatic Solid Tumors
Suzhou Transcenta Therapeutics Co., Ltd.
Phase 1/2 Recruiting
NCT03369223 2025-11-18
A Study of BMS-986249 Alone and in Combination With Nivolumab in Advanced Solid Tumors
Bristol-Myers Squibb
Phase 1/2 Completed
NCT03446040 2025-09-18
An Investigational Immunotherapy Study of BMS-986258 Alone and in Combination With Nivolumab in Participants With Solid Cancers That Are Advanced or Have Spread
Bristol-Myers Squibb
Phase 1/2 Terminated
NCT03110107 2025-04-24
First-In-Human Study of Monoclonal Antibody BMS-986218 by Itself and in Combination With Nivolumab in Participants With Advanced Solid Tumors
Bristol-Myers Squibb
Phase 1/2 Terminated
NCT05154630 2024-01-18
Study on Tolerability and Pharmacokinetics of TQB2858 Injection in Subjects With Advanced Malignant Tumors
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 1/2 Terminated
NCT02341625 2022-08-18
A Study of BMS-986148 in Patients With Select Advanced Solid Tumors
Bristol-Myers Squibb
Phase 1/2 Terminated
NCT03792750 2022-02-28
A Study of BMS-986205 Alone and in Combination With Nivolumab in Chinese Patients With Advanced Malignant Solid Tumors
Bristol-Myers Squibb
Phase 1/2 Completed
NCT02737475 2022-01-25
An Investigational Immuno-Therapy Study of Experimental Medication BMS-986178 by Itself or in Combination With Nivolumab and/or Ipilimumab in Participants With Solid Cancers That Are Advanced or Have Spread
Bristol-Myers Squibb
Phase 1/2 Completed
NCT04376931 2020-07-29
A Prospective Dose Finding Study of Iscador Infusion
HaEmek Medical Center, Israel
Phase 1/2 Unknown
NCT04124666 2019-12-19
Clinical Study of Granulocyte Infusion for Advanced Cancer
Shanghai East Hospital
Phase 1/2 Unknown
NCT00785226 2016-10-17
RDEA119 and Sorafenib Combination Dose Escalation Study
Bayer
Phase 1/2 Completed